STAT+: UnitedHealth’s Democrat investment, and surprise billing bloat debate
UnitedHealth execs shower a top Democrats with cash, and the No Surprises Act debate heats up.
Read at STAT News · 8 September 2026 at 14:51
STAT+: UnitedHealth’s Democrat investment, and surprise billing bloat debate
All coverage of this event, automatically grouped from multiple independent sources.
Last updated: 8 September 2026 at 17:09 · 8 articles · 1 sources
STAT+: Health care features prominently in Democrats’ agenda
Democrats are sharpening their health care plans as the midterm elections near.
Read at STAT News · 8 September 2026 at 14:22
STAT+: Oura goes public, reported $1.2B earnings in its last fiscal year
In health tech news today, Oura reports a profit, the FDA loses another key digital health leader, and more
Read at STAT News · 8 September 2026 at 14:18
STAT+: FDA approves AstraZeneca breast cancer drug
Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs, and more biotech news
Read at STAT News · 8 September 2026 at 14:09
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study
Read at STAT News · 8 September 2026 at 13:26
STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.
Read at STAT News · 8 September 2026 at 11:45
STAT+: Inhibrx claims first win for long-sought immunotherapy target
“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
Read at STAT News · 8 September 2026 at 11:30
STAT+: Roivant lung disease drug hits mid-stage study goals
These positive results could open up a new way to treat serious lung disease.
Read at STAT News · 8 September 2026 at 10:00